<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180223038837N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-12-08</date_registration>
      <primary_sponsor>Kermanshah University of Medical Sciences</primary_sponsor>
      <public_title>Comparative study of radiofrequency ablation &amp; foam sclerotherapy for treatment patients suffering from varicose veins</public_title>
      <acronym></acronym>
      <scientific_title>Comparative study of radiofrequency ablation &amp; foam sclerothrapy for treatment patients suffering from great saphenous varicose vein</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/32039</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: A total of 60 patients with entering criteria were selected by available sampling. Then, randomly using a random number table, they are placed in one of two groups of foam sclerotherapy and RFA.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Varicose veins of lower extremities.</hc_freetext>
      <i_freetext>Intervention 1: Interventional Group 1: This group treated with radiofrequency ablation .Treatment includes segmental thermal ablation  of great saphenous vein through a catheter by seven-centimeters element  . thermal ablation started  two centemeters of  below the saphenofemoral junction. In each segment, temperature remains at about 120 degree centegrades for 20 seconds. In this project used  radiofrequency catheter for Covidian brand, made in Costa Rica, to do ablation. Intervention 2: Intervention group 2(Foam sclerotherapy): This group will be  treated with  Foam sclerotherapy . Foam includes fibrovein with air with a ratio of one- fifth (with Tesari Method) is mixed and  injected into the vein Under ultrasound guidance. It continues as long as the foam reaches of two centimeter of saphenofemoral junction and causes ablation in the vein Endothelium by chemical inflammation. In this project, Sclerosing substance of fibrovein brand, made in England , is used for foam sclerotherapy.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
In the case of the participant's data file, three months after the publication of the article, and after unidentification of the persons, the request can be sent by email.

When:
Three months after the publication of the article, upon request, by email, there is a possibility to post.

To whom:
Only scholars working in academic and scientific institutions

Conditions:
The name of the first author of the study is required in an extracted article from the study data. In this case, it is possible to perform any statistical analysis.

Where to obtain:
Correspondence by e-mail with the Doctor Mohammadreza Sobhiyeh.
Email: mreza.sobhiyeh@yahoo.com

How to obtain:
Up to one week after receipt of the email, the requested documentation is sent.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Reza Sobhiyeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Reza Hospital., Parastar Blvd.</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>671441533</zip>
        <telephone>+98 83 3427 6333</telephone>
        <email>mreza.sobhiyeh@yahoo.com</email>
        <affiliation>Kermanshah University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Reza Sobhiyeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam reza hospital-parastar Ave-kermanshah</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>671441533</zip>
        <telephone>+98 83 3427 6333</telephone>
        <email>mreza.sobhiyeh@yahoo.com</email>
        <affiliation>Kermanshah University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Conscious patient consent to enter the study
The patient suffers from great saphenous varicose vein
No history of varicose vein
The diameter of the great saphenous vein at 3 cm below the saphenophemoral junction in Doppler sonography is between 10 to 20 mm.
No duplication of varicose vein
Non-use of anti-coagulans and antiplatelet drugs
No history of vascular insufficiency</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Failure to collaborate for follow-up</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I83</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Varicose veins of lower extremities</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Interventional Group 1: This group treated with radiofrequency ablation .Treatment includes segmental thermal ablation  of great saphenous vein through a catheter by seven-centimeters element  . thermal ablation started  two centemeters of  below the saphenofemoral junction. In each segment, temperature remains at about 120 degree centegrades for 20 seconds. In this project used  radiofrequency catheter for Covidian brand, made in Costa Rica, to do ablation.</i_keyword>
      <i_keyword>Intervention group 2(Foam sclerotherapy): This group will be  treated with  Foam sclerotherapy . Foam includes fibrovein with air with a ratio of one- fifth (with Tesari Method) is mixed and  injected into the vein Under ultrasound guidance. It continues as long as the foam reaches of two centimeter of saphenofemoral junction and causes ablation in the vein Endothelium by chemical inflammation. In this project, Sclerosing substance of fibrovein brand, made in England , is used for foam sclerotherapy.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Recurrence of Varicose Veins. Timepoint: One week, one month, three months, six months and 12 months after treatment. Method of measurement: Color Doppler Ultrasonography.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Quality of life. Timepoint: Before  and a week after treatment. Method of measurement: SF-36 questionnaire.</sec_outcome>
      <sec_outcome>Intensity of pain. Timepoint: Before and a week after treatment. Method of measurement: Visual Analoge Scale.</sec_outcome>
      <sec_outcome>Condition of Varicose veins. Timepoint: Before and a week after treatment. Method of measurement: Aberdeen Varicose Veins Questionnaire.</sec_outcome>
      <sec_outcome>The interval between the treatment process and the return to usual life. Timepoint: after treatment. Method of measurement: The patient is asked.</sec_outcome>
      <sec_outcome>The cost of treatment. Timepoint: After treatment. Method of measurement: Documentation file.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kermanshah University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-09-23</approval_date>
        <contact_name>Ethics Committee of Kermanshah University of Medical Sciences</contact_name>
        <contact_address>Imam Reza Hospital, Parastar Blvd Kermanshah Kermanshah Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
